Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
NCT ID: NCT02028663
Last Updated: 2014-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
206 participants
INTERVENTIONAL
2013-05-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
NCT02456935
Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
NCT03006874
A Study to Compare the Pharmacokinetic Characteristics of CJ-12420
NCT02995239
JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis
NCT05443984
Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis
NCT03615677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CJ-12420 Amg
50 volunteers will be administered CJ-12420 Amg
CJ-12420
Once daily, Oral administration
CJ-12420 Bmg
50 volunteers will be administered CJ-12420 Bmg
CJ-12420
Once daily, Oral administration
CJ-12420 Cmg
50 volunteers will be administered CJ-12420 Cmg
CJ-12420
Once daily, Oral administration
Esomeprazole 40mg
50 volunteers will be administered Esomeprazole 40mg
Esomeprazole
Once daily, Oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CJ-12420
Once daily, Oral administration
Esomeprazole
Once daily, Oral administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified into LA Grade A to D within 14 days before randomization to treatment
Exclusion Criteria
* Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected IBS
* Patients who took PPIs within 2 weeks prior to study drug administration
* Long-term use of nonsteroidal anti-inflammatory drugs throughout the study
* Clinically significant abnormal laboratory values during screening
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HK inno.N Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyun-Chae Jung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital and 11 others
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CJ_APA_201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.